Emerging muscarinic receptor antagonists for the treatment of asthma.

Emerging muscarinic receptor antagonists for the treatment of asthma. Expert Opin Emerg Drugs. 2020 Apr 21;: Authors: Matera MG, Belardo C, Rinaldi M, Rinaldi B, Cazzola M Abstract Introduction: The critical role of acetylcholine in asthma pathophysiology and the increase in vagal tone are the main reasons why a LAMA is a good choice in the treatment of the asthmatic patient. Tiotropium is the only LAMA approved for use in asthma in many countries but there is a real interest in developing novel LAMAs for the treatment of asthma, or at least to extend this indication to other LAMAs already on the market.Areas covered: Trials that have studied or are evaluating the role of LAMAs already on the market in asthma and possible novel muscarinic acetylcholine receptor antagonists have been examined and discussed.Expert opinion: It is likely that glycopyrronium and umeclidinium will also be included in the GINA strategy with the same current indications of tiotropium. Probably the choice of the LAMA will be related to reasons other than its mere pharmacological profile and will be mainly related to the type of triple therapy chosen. Since it is extremely difficult to identify a new LAMA that is more effective than tiotropium, we believe that new technologies that will allow delivering the drug in a more targeted way and with a lower risk of adverse effects may represent the real progress in the use of LAMAs in asthma in the coming years. ...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research